Chain-end modifications and sequence arrangements of antimicrobial peptoids for mediating activity and nano-assembly by Hasan, Abshar et al.
  
 
Chain-End Modifications and Sequence
Arrangements of Antimicrobial Peptoids
for Mediating Activity and
Nano-Assembly
 
Abshar Hasan1, 2, Varun Saxena2, 1, Valeria Castelletto3, Georgina Zimbitas4, Jani Seitonsen5,
Janne Ruokolainen5, Lalit M. Pandey2, Jan Sefcik4, Ian W. Hamley6, King Hang Aaron Lau1*
 
1Department of Pure and Applied Chemistry, University of Strathclyde, United Kingdom, 2Department
of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, India, 3Department of
Chemistry, University of Reading, United Kingdom, 4Department of Chemical and Process Engineering,
University of Strathclyde, United Kingdom, 5Nanomicroscopy Center, School of Science, Aalto University,
Finland, 6University of Reading, United Kingdom
 Submitted to Journal:
 Frontiers in Chemistry
 Specialty Section:
 Chemical Biology
 Article type:
 Original Research Article
 Manuscript ID:
 536818
 Received on:
 21 Feb 2020
 Revised on:
 15 Apr 2020
 Frontiers website link:
 www.frontiersin.org
In r vi
ew
  
 Conflict of interest statement
 The authors declare that the research was conducted in the absence of any commercial or financial
relationships that could be construed as a potential conflict of interest
  
 Author contribution statement
 
AH, synthesized all the peptoid designs and performed HPLC, LC-MS, MIC and CAC analysis. VS performed MIC tests. VC and IWH
performed and analyzed SAXS results. GZ and JS performed DLS measurements and analysis. JS and JR performed and analyzed
cryo-EM data. KHAL and AH conceptualized the work, analyzed the data and wrote the original draft. LMP and KHAL supervised AH
and VS.
  
 Keywords
 
Self-assambly, Antimicrobial peptide (AMP), peptoid, DLS (dynamic light scattering), SAXS (small-angle X-ray scattering), Critical
aggregate concentration, Minimum inhibiting concentrations, E. coli - Escherichia coli, Pseudomonas aeruginosa, Staphalococcus
aureus, Lipopeplide, lipopeptoid, peptide amphiphile, micelle •nanotechnology
  
 Abstract
Word count: 319
 
Poly(N-substituted glycine) “peptoids” are an interesting class of peptidomimics that can resist proteolysis and mimic naturally
found antimicrobial peptides (AMPs), which exhibit wide spectrum activity against bacteria. This work investigates the possibility
of modifying peptoid AMP mimics (AMPMs) with aliphatic lipid “tails” to generate “lipopeptoids” that can assemble into micellar
nanostructures, and evaluates their antimicrobial activities. Two families of AMPMs with different distributions of hydrophobic and
cationic residues were employed—one with a uniform repeating amphiphilicity, the other with a surfactant-like head-to-tail
amphiphilicity. To further evaluate the interplay between self-assembly and activity, the lipopeptoids were variously modified at
the AMPM chain ends with a diethylene glycol (EG2) and/or a cationic group (Nlys-Nlys dipeptoid) to adjust amphiphilicity and chain
flexibility. Self-assembly was investigated by critical aggregation concentration (CAC) fluorescence assays and dynamic light
scattering (DLS). The structure of a key species was also verified by small-angle X-ray scattering (SAXS) and cryo-electron
microscopy (cryo-EM). To screen for antibacterial properties, we measured the minimum inhibitory concentrations (MIC) against S.
aureus, E. coli and P. aeruginosa. We found that certain combinations of lipid tail and AMPM sequences exhibit increased
antibacterial activity (i.e. decreased MICs). Perhaps counter-intuitively, we were particularly interested in increased MICs in
combination with low CACs. Concealing antimicrobial interactions due to packing of AMPMs in nano-assemblies could pave the way
to AMPMs that may be “inert” even if unintentionally released and prevent microbes from gaining resistance to the lipopeptoids.
Overall, incorporation of EG2 significantly improved lipopeptoids packing while the hydrophobic tail length was found to have a
major influence over the MIC. One particular sequence, which we named C15‐EG2‐(kss)4, exhibited a very low CAC of 34  M
(0.0075 wt.%) and a significantly increased MIC above values for the unmodified AMPM. With the sequence design trends uncovered
from this study, future work will focus on discovering more species such as C15-EG2-(kss)4 and on investigating release
mechanisms and the potency of the released lipopeptoids.
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Abstract 1 
Poly(N-substituted glycine) “peptoids” are an interesting class of peptidomimics that can resist 2 
proteolysis and mimic naturally found antimicrobial peptides (AMPs), which exhibit wide 3 
spectrum activity against bacteria. This work investigates the possibility of modifying peptoid 4 
AMP mimics (AMPMs) with aliphatic lipid “tails” to generate “lipopeptoids” that can assemble 5 
into micellar nanostructures, and evaluates their antimicrobial activities. Two families of AMPMs 6 
with different distributions of hydrophobic and cationic residues were employed—one with a 7 
uniform repeating amphiphilicity, the other with a surfactant-like head-to-tail amphiphilicity. To 8 
further evaluate the interplay between self-assembly and activity, the lipopeptoids were variously 9 
modified at the AMPM chain ends with a diethylene glycol (EG2) and/or a cationic group (Nlys-10 
Nlys dipeptoid) to adjust amphiphilicity and chain flexibility. Self-assembly was investigated by 11 
critical aggregation concentration (CAC) fluorescence assays and dynamic light scattering (DLS). 12 
The structure of a key species was also verified by small-angle X-ray scattering (SAXS) and cryo-13 
electron microscopy (cryo-EM). To screen for antibacterial properties, we measured the minimum 14 
inhibitory concentrations (MIC) against S. aureus, E. coli and P. aeruginosa. We found that certain 15 
combinations of lipid tail and AMPM sequences exhibit increased antibacterial activity (i.e. 16 
decreased MICs). Perhaps counter-intuitively, we were particularly interested in increased MICs 17 
in combination with low CACs. Concealing antimicrobial interactions due to packing of AMPMs 18 
in nano-assemblies could pave the way to AMPMs that may be “inert” even if unintentionally 19 
released and prevent microbes from gaining resistance to the lipopeptoids. Overall, incorporation 20 
of EG2 significantly improved lipopeptoids packing while the hydrophobic tail length was found 21 
to have a major influence over the MIC. One particular sequence, which we named C15-EG2-(kss)4, 22 
exhibited a very low CAC of 34 µM (0.0075 wt.%) and a significantly increased MIC above values 23 
for the unmodified AMPM. With the sequence design trends uncovered from this study, future 24 
work will focus on discovering more species such as C15-EG2-(kss)4 and on investigating release 25 
mechanisms and the potency of the released lipopeptoids. 26 
 27 
1.  Introduction 28 
Past decades witnessed significant increase in antimicrobial resistance (AMR) causing a large 29 
burden on healthcare [1, 2]. Antibiotic drugs have enabled modern medicine by treating microbial 30 
infection. However, their specific mechanisms of binding to cellular molecular targets enables 31 
bacteria to develop resistance [3]. Hence, new antimicrobials need to be developed, especially 32 
those that exhibit different or broad-spectrum bactericidal activity. For example, various peptides 33 
and polymers designs have been proposed to disrupt bacterial membranes by broadly utilizing 34 
electrostatic interactions with subsequent pore generation [4, 5]. Moreover, antimicrobial peptides 35 
(AMPs) expressed by many living species as a defense mechanism against other bacteria, fungi 36 
and viruses, have been proposed as an alternative to antibacterial and antifungal drugs [6-8]. 37 
However, peptides, especially oligomeric species exhibiting antimicrobial activity, are prone to 38 
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biodegradation under the effect of bacterial and other extracellular proteases. To overcome such 39 
limitations, there is a significant drive to generate more stable peptidomimics [2, 4, 9]. 40 
Inspired by the diverse nanostructures and biofunctionality of natural peptides, peptide 41 
amphiphiles (or lipopeptides) with one or more lipid tails attached to an (amphiphilic) peptide head 42 
group have been a focus of biomaterials research. Depending on the peptide sequence and the 43 
length of the hydrophobic “tail”, these surfactant-like molecules can self-assembly into 44 
nanoassemblies such as micelles, nanofibrils, nanotapes, rods, vesicles, etc. [10]. Demonstrations 45 
of a range of applications in food safety and therapeutics, drug delivery, crop protection and other 46 
biomedical applications have been reported [10-12]. However, as peptide materials, they do not 47 
address the problem of proteolytic degradation.  48 
Peptoids are a recently developed class of peptidomimics [13]. Their sidechains are attached to the 49 
amide nitrogen of N-substituted glycine residues, rather than to the backbone α-carbons as in 50 
peptides [13], thus preventing their recognition by proteases and enabling resistance against 51 
proteolysis. This sidechain shift also results in an achiral backbone and preclusion of inter- and 52 
intra-backbone hydrogen bonding, and hence backbone conformational flexibility is enhanced [14, 53 
15]. Bioactivity and formation of secondary and supramolecular structures are therefore tailored 54 
based predominantly on side-chain sequence selection [15, 16]. A powerful advantage of peptoids 55 
is the ‘submonomer’ solid phase synthesis approach for conveniently generating sequences with 56 
diverse natural and non-natural sidechains [15, 17, 18]. Antimicrobial and antifouling peptoids 57 
sequences [19-21], anti-biofouling surfaces [22], applications in drug discovery [23], diagnosing 58 
amyloid proteins [24], etc., have all been reported. Peptoid self-assembly is a rapidly emerging 59 
area, and a number of groups have reported a variety of nanostructures, including micelles [17], 60 
nanotubes [25], and nanosheets [26, 27]. However, the interplay between self-assembly and 61 
bioactivity is still less explored.  62 
In this work, we report the design, synthesis and characterization of amphiphilic lipopeptoids as 63 
potential self-assembling antimicrobials. Previous work by Findlay et al. demonstrated the 64 
replacement of cationic lipopeptides with lipopeptoids without affecting their antimicrobial 65 
activities [28]. However, they did not emphasize the self-assembly of their lipopeptoids and their 66 
bioactivity thereafter. We have previously demonstrated the predictable formation of ultra-small 67 
and highly stable spherical micelles from “lipopeptoids” comprising of a lipid tail coupled to an 68 
amphiphilic peptoid oligomer [17]. We have now generated a set of bioactive lipopeptoids by 69 
coupling existing high-potency peptoid AMPMs (antimicrobial peptide mimics), originally 70 
reported by the Barron [29] and Hansen [30] groups, to hydrophobic lipid tails of different lengths 71 
(i.e. C8, C11 and C15). Further insertions of ethylene glycol (EG2) at the N-terminus of the AMPM 72 
and a pair of cationic residues at the C-terminus were explored for controlling self-assembly and 73 
antibacterial behavior. Self-assembly was characterized by critical aggregation concentration 74 
(CAC) fluorescence assays and dynamic light scattering (DLS), supplemented by cryo-75 
transmission electron microscope (cyro-TEM) and small angle X-ray scattering (SAXS). 76 
Minimum inhibitory concentration (MIC) assays against the Gram positive Staphylococcus aureus 77 
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and Gram negative Pseudomonas aeruginosa and Escherichia coli were used to screen for changes 78 
in antimicrobial activity of our library compared to the native AMPMs. While it may be anticipated 79 
that specific sequences might be discovered to exhibit enhanced antimicrobial activity and/or 80 
propensity for self-assembly after chain end modifications, we were also interested in discovering 81 
sequences with increased MICs above their CACs. Such cases could indicate “packaging” of 82 
antimicrobial sequences into inactive nanostructured delivery vehicles, which could later be 83 
triggered for nanostructure disassembly and release of the lipopeptoids. This could provide an 84 
approach for preventing microbes from gaining exposure to the AMPMs if the lipopeptoids were 85 
unintentionally released into such an environment, thereby acquiring resistance.   86 
2. Material and methods 87 
2.1. Materials 88 
All solvents (HPLC grade) and chemicals used were purchased from Sigma-Aldrich UK, unless 89 
otherwise specified. Rink amide MBHA resin was bought from Merck, UK. Tert-butyl N-(4-90 
aminobutyl) carbamate (NLys) and (1S)-1-Phenylethylamine (Nspe) monomers were purchased 91 
from Apollo scientific, UK. Fmoc-Amino-3,6 dioxaoctanoic acid was procured from FluroChem, 92 
UK. 93 
2.2. Lipopeptoids synthesis 94 
Peptoids were manually synthesized on resin using a solid phase ‘submonomer’ approach [15, 17, 95 
18]. Briefly, the Fmoc protected rink amide resin was deprotected with 20% piperidine for 20 96 
minutes, applied twice. Each residue was added by treatment to a mixture of bromoacetic acid (20 97 
times excess) and diisopropyl-carbodiimide (18.5 times excess) for 15 min, followed by a halo-98 
substitution reaction with appropriate primary amine submonomers. For the attachment of a di 99 
ethylene glycol linker, Fmoc-amino-3,6 dioxaoctanoic acid (1.8 mmol) and equivalent moles of 100 
HBTU ((2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) were reacted 101 
with the terminal amino group in the presence of N,N-Diisopropylethylamine (DIPEA, 2.7 mmol). 102 
This reaction was carried out for 2 h at 37°C and repeated a second time for 4 h, to ensure coupling. 103 
Like resin Fmoc deprotection, EG2 N-terminal Fmoc deprotection was achieved using 20% 104 
piperidine for 20 minutes, applied twice. Different chain lengths of saturated fatty acids, i.e. 105 
nonanoic acid (C8), lauric acid (C11) and palmitic acid (C15) were subsequently coupled using the 106 
HBTU amide coupling as reported previously [17]. After solid phase synthesis, the resin was 107 
cleaved and side chains were deprotected for 30 min using a standard TFA:TIPS:H2O cocktail 108 
(95:2.5:2.5 v/v/v). Excess TFA was removed using a rotary evaporator and the peptoid was 109 
precipitated from the oily product using diethyl ether. The collected material was dissolved in 110 
small amounts of 1:1 acetonitrile:water (ACN:H2O) to ease sample transfer, and further dried in a 111 
lyophilizer. Dried crude products were weighed and dissolved in ACN-H2O mixtures for 112 
preparative RP-HPLC (Dionex Ultimate 3000) with a C18 column (250x10 mm Phenomenex 113 
Jupiter). Fractions containing the pure product were identified by ESI-LC-MS (Agilent 1200 with 114 
a Poroshell C18 column coupled to an Agilent 6130 mass spectrometer) and by analytical RP-115 
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HPLC (Dionex P680) using a C18 column (250x4.6 mm “Nucleosil”) with a 30 min gradient of 116 
5−95% acetonitrile (ACN) in water containing 0.1% TFA at 1 mL/min. The purified fractions of 117 
peptoids and lipopeptoids were later stored as aliquots at -20°C until further analysis. The 118 
analytical HPLC and ESI-MS data are shown in Figures S1-S5.  119 
2.3. Dynamic Light Scattering (DLS) Analysis 120 
DLS measurements were carried out at room temperature (25°C) using an ALV/LSE-5004 121 
instrument equipped with He-Ne laser (λ = 632.8 nm) at a detection angle of θ = 90° [17]. Samples 122 
were prepared at a concentration of 0.4 wt.% in deionized water (DI) water and further filtered 123 
using 0.22 µm pore size surfactant-free cellulose acetate (SFCA) syringe filters (Sigma Aldrich, 124 
UK) to avoid particulate contamination. 125 
2.4. Cryogenic Transmission Electron Microscopy (Cryo-TEM) 126 
Sizes of selected lipopeptoids’ nano-assemblies were verified using a field emission cryo-electron 127 
microscope (JEOL JEM3200FSC), operating at 200 kV and at -187 °C, configured in bright field 128 
mode and zero loss energy filtering (omega type) with a slit width of 20 eV. Sizes of selected 129 
lipopeptoids nano-assemblies were measured from photographs recorded using a Gatan Ultrascan 130 
4000 CCD camera. Vitrified specimens were prepared on Quantifoil 3.5/1 holey carbon copper 131 
grids (hole size of 3.5 μm). The grids were first plasma cleaned using a Gatan Solarus 9500 plasma 132 
cleaner and then transferred into the environmental chamber of an automated FEI Vitrobot device 133 
at room temperature and 100% humidity. Thereafter, 3 μL of the sample solution was applied on 134 
the grid, which was blotted twice for 5 s and then vitrified in a 1:1 mixture of liquid ethane and 135 
propane at a temperature of −180 °C. The grids with vitrified sample solution were maintained at 136 
liquid nitrogen temperature and then cryo-transferred to the microscope. 137 
2.5. Small angle X-ray Scattering (SAXS) 138 
SAXS experiments were performed on the bioSAXS beamline B21 at Diamond Light Source, 139 
U.K., using previously established protocol [27]. Briefly, solutions containing 1 wt.% peptoid were 140 
loaded on a set of PCR tubes fitted in the 96-well plate of the BioSAXS robot. From there, the 141 
robot loaded the solutions into a quartz capillary perpendicularly placed in the path of the incident 142 
X-ray beam. SAXS data, collected using a Dectris PILATUS 2 M detector at a fixed camera length 143 
of 3.9 m, is presented as scattering intensity vs. q = 4π sinθ /λ (2θ: scattering angle; wavelength: λ 144 
= 1 Å). See SI for description of SAXS data fitting . 145 
2.6. Critical Aggregation Concentration (CAC) Assay 146 
Nile red (NR) fluorescence was used to measure critical aggregation concentration (CAC) for the 147 
synthesized lipopeptoids. Lipopeptoids were dissolved at 2.5x10-2 to 1 wt.% in a dilute solution of 148 
Nile Red (0.25 µg/100 mL, i.e. ~10 nM concentration) prepared in water. NR was excited at 552 149 
nm and emission was recorded at room temperature in the range 550 to 750 nm using a 10.0 × 5.0 150 
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mm2 quartz cell (Jasco spectrofluorimeter FP-6500). The intensity of the peak centered around 610 151 
nm is shown in the data presented in Section 3. 152 
2.7. Antibacterial analysis 153 
Minimum inhibitory concentration (MIC) analysis was performed against Gram positive 154 
(Staphylococcus aureus (NCTC 4135), and Gram negative (Escherichia coli (ATCC 25922) and 155 
Pseudomonas aeruginosa (PA01)) strains. Analysis was performed in Mueller–Hinton (MH) broth 156 
using broth microdilution method (CLSI M07-A10) in 96 well plates [31]. Bacterial strains 157 
(~5x105 CFU/mL) with different concentrations of peptoids and lipopeptoids were incubated 158 
overnight at 37°C. Optical density (OD) was recorded at 600 nm using a plate reader (Infinite 200 159 
Pro, Tecan). The MIC value (concentration for which the OD was halfway between the minimum 160 
and maximum values) was obtained by fitting the OD data to a sigmoidal model using Origin 161 
software, which also computed the standard deviation. Technical triplicates (n=3) or more of 162 
samples at each concentration were analyzed. 163 
 164 
3. Results and discussion 165 
3.1. Design of Lipopeptoids based on (kss)4 and 4/5k Antimicrobial Sequences 166 
The basic peptoid design follows our earlier work that attached a palmitic acid (C15) hydrophobic 167 
lipid tail to the N-terminus of oligopeptoids 6-8 residues long [17]. These earlier oligopeptoids 168 
were typified by a short amphiphilic segment with alternating hydrophobic/hydrophilic residues 169 
and a cationic, highly soluble C-terminal Nlys-Nlys “kk” dipeptoid, inserted with the intention to 170 
increase water solubility. Self-assembly of the resulting lipopeptoids was strongly driven by the 171 
hydrophobic lipid tail and the relatively bulky, but water soluble oligopeptoid.  172 
In this study, we postulate that nano-assemblies can likewise be formed from lipopeptoids prepared 173 
by attaching lipid tails to the chain ends (i.e. C- and N- termini) of known antimicrobial 174 
amphiphilic oligopeptoids (Figure 1). To investigate the scope of this approach, we included two 175 
families of antimicrobial peptoids (AMPMs) for modification, one reported by Barron et al. [29, 176 
32] and the other by Ryge and Hansen [30]. These AMPMs were chosen not only for demonstrated 177 
effectiveness against a wide spectrum of bacteria but also for possessing different distributions of 178 
amphiphilicity along their sequences. Moreover, the two families exhibit different sequence 179 
distribution of cationic and hydrophobic residues. Barron group’s helical AMPMs are typified by 180 
multiple repeats of an amphiphilic Nlys-Nspe-Nspe trimeric motif, which we designated as “kss”, 181 
with the small letters k and s denoting Nlys and Nspe residues, respectively (Figure 1B and C). 182 
We selected three AMPMs from the Ryge and Hansen study consisting of several consecutive 183 
cationic Nlys residues at the C-terminus followed by a hydrophobic segment of similar length. The 184 
corresponding lipopeptoids are designated as the 4/5k family since one sequence has four 185 
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consecutive C-terminal Nlys residues (4k), another has five (5k), and the third has an alternating 186 
amphiphilic C-terminal “kykbk” sequence (Figure 1D and E) [30].  187 
 188 
 189 
Figure 1. Chemical structures of A) peptoid monomers, B) the AMPM (kss)n, where n = 2, 3, or 190 
4, C) C- and N-terminal modifications of the kss family of lipopeptoids, D) the Nlys-rich 4k, 5k, 191 
and kykxk AMPs from Hansen’s work [30], and E) the corresponding 4/5k family of lipopeptoids.   192 
 193 
To study how the AMPM sequences need to be balanced by the lipid tail and other components to 194 
obtain high assembly propensities, we included designs with different lengths of the hydrophobic 195 
aliphatic tail (C8, C11, C15). For the kss motif we also studied lipopeptoids with varying AMPM 196 
motif lengths (i.e. (kss)n, where n = 2, 3, 4). While longer hydrophobic tails (C8, C11, C15) should 197 
promote assembly of hydrophobic cores, the effect of repeating the kss motif is less clear. 198 
However, it has been shown that longer kss sequences are more potent AMPMs [16]. In addition, 199 
analogous to our initial lipopeptoid report [17], we inserted the cationic C-terminal “kk” dipeptoid 200 
s = N-(S)-(1-
Phenylethyl) glycine
k = N-(4-
aminobutyl) glycine
(Nlys-Nspe-Nspe)n = (kss)n
where n= 2, 3, 4
R1 R2
(kss)n : H NH2
C8-EG2-(kss)n-kk :
C11-EG2-(kss)n-kk :
C15-EG2-(kss)n-kk :
C15-(kss)n-kk :
C15-EG2-(kss)n : NH2
(A)
(B)
(C)
b = N-(Butyl) 
glycine
y = N-(1-
Naphthalenemethyl) 
glycine
z = N-(4-
Methylbenzyl) 
glycine
C8-EG2-4k :
C8-EG2-5k :
C8-EG2-kykbk :
R1
C15-EG2-4k :
C15-EG2-5k :
C15-EG2-kykbk :
4k :
5k :
Kykbk :
(D)
(E)
kss family 4/5k family
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with the intention of creating a more water soluble “headgroup”. A new feature, a flexible 201 
diethylene glycol hydrophilic linker (EG2) is introduced between the AMPM and the lipid tail, 202 
since our earlier study indicated that flexibility along the sequence could promote assembly of 203 
more compact and stable micelles. The exact sequences, bioactivity and self-assembly parameters 204 
(i.e. MIC and CAC) of all designs are listed in Table 1.   205 
Table 1. Characteristics of antimicrobial peptoids and lipopeptoids designs tested and measured 206 
values of CAC and MIC (see sections 3.2 to 3.4 for description). 207 
Compound name Sequence MW CAC 
(µM) 
Antimicrobial activity 
S. aureusΨ 
(µM) 
E. coli* 
(µM) 
P. aeruginosa# 
(µM) 
(kss)2 H-(Nlys-Nspe-Nspe)2-NH2 918 NA 41±2 >100 44±2 
(kss)3 H-(Nlys-Nspe-Nspe)3-NH2 1369 NA 2±0.2 4±0.2 15±1 
(kss)4 H-(Nlys-Nspe-Nspe)4-NH2 1819 NA 4±0.3 6±0.4 16 ±0.3 
C8-EG2-(kss)2-kk CH3(CH2)7-(OCH2CH2)2O)-(Nlys-
Nspe-Nspe)2-Nlys-Nlys-NH2 
1459 200±37 9±1 18±3 13±3 
C8-EG2-(kss)3-kk CH3(CH2)7-(OCH2CH2)2O)-(Nlys-
Nspe-Nspe)3-Nlys-Nlys-NH2 
1909 270±30 3±1 2±0.3 6±2 
C8-EG2-(kss)4-kk CH3(CH2)7-(OCH2CH2)2O)-(Nlys-
Nspe-Nspe)4-Nlys-Nlys-NH2 
2360 290±14 2±0.1 2±0.3 2±0.4 
C11-EG2-(kss)2-kk CH3(CH2)10-(OCH2CH2)2O)-(Nlys-
Nspe-Nspe)2-Nlys-Nlys-NH2 
1501 200±17 7±1 9±1 19±1 
C11-EG2-(kss)3-kk CH3(CH2)10-(OCH2CH2)2O)-(Nlys-
Nspe-Nspe)3-Nlys-Nlys-NH2 
1951 310±38 1±0.1 3±0.2 15±0.4 
C11-EG2-(kss)4-kk CH3(CH2)10-(OCH2CH2)2O)-(Nlys-
Nspe-Nspe)4-Nlys-Nlys-NH2 
2402 270±31 2±0.2 7±0.1 14±1 
C15-(kss)4-kk CH3(CH2)14-(Nlys-Nspe-Nspe)4-
NlysNlys-NH2 
2315 300±25 >100 >100 >100 
C15-EG2-(kss)4-kk CH3(CH2)14-(OCH2CH2)2O)-(Nlys-
Nspe-Nspe)4-Nlys-Nlys-NH2 
2458 180±11 36±5 44±5 >100 
C15-EG2-(kss)4 CH3(CH2)14-(OCH2CH2)2O)-(Nlys-
Nspe-Nspe)4-NH2 
2201 38±3 50±1 >100 >100 
4k H-(Nnme-Nmbe-Nnme-Nbut-
(Nlys)4)-NH2 
1198 NA 7±0.1 7±0.3 19±0.4 
5k H-(Nnme-Nmbe-Nnme-Nbut-
(Nlys)5)-NH2 
1326 NA 8±0.1 7±0.2 33±1 
Kykbk H-(Nnme-Nlys-Nmbe-Nlys-Nnme-
Nlys-Nbut-Nlys)-NH2 
1198 NA 9±0.4 15±1 20±1 
C8-EG2-4k CH3(CH2)7-(OCH2CH2)2O)-(Nnme-
Nmbe-Nnme-Nbut-(Nlys)4)-NH2 
1483 2500±350 18±3 17±1 16±2 
C8-EG2-5k CH3(CH2)7-(OCH2CH2)2O)-(Nnme-
Nmbe-Nnme-Nbut-(Nlys)5)-NH2 
1611 1600±390 8±0.3 74±4 41±2 
C8-EG2-kykbk CH3(CH2)7-(OCH2CH2)2O)-(Nnme-
Nlys-Nmbe-Nlys-Nnme-Nlys-Nbut-
Nlys)-NH2 
1483 1900±200 2±0.2 11±4 15±3 
C15-EG2-4k CH3(CH2)14-(OCH2CH2)2O)-(Nnme-
Nmbe-Nnme-Nbut-(Nlys)4)-NH2 
1581 320±24 >100 >100 >100 
C15-EG2-5k CH3(CH2)14-(OCH2CH2)2O)-(Nnme-
Nmbe-Nnme-Nbut-(Nlys)5)-NH2 
1709 360±25 >100 75±10 >100 
C15-EG2-kykbk CH3(CH2)14-(OCH2CH2)2O)-(Nnme-
Nlys-Nmbe-Nlys-Nnme-Nlys-Nbut-
Nlys)-NH2 
1581 410±32 72±20 35±18 >100 
NA: Not Applicable; ΨNCTC 4135; *ATCC 25922; # PA01 208 
 209 
3.2. Self-Assembly of kss Lipopeptoids  210 
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We first examined with a CAC assay whether coupling a hydrophobic tail to AMPMs and inserting 211 
the kk and EG2 components is a viable design for generating self-assembling lipopeptoids. The 212 
CAC measures the concentration above which hydrophobic pockets (e.g. lipophilic cores of 213 
micelles) are formed, and lower CACs indicate higher propensities of self-assembly. In our 214 
experiments, the CAC is indicated by an inflection in the increase in emission intensity of a 215 
lipophilic fluorophore tracer (Nile Red) that emits more strongly when partitioned into 216 
hydrophobic lower dielectric environments (see Figure S6 for an example analysis).  217 
Taking the highly potent (kss)4 sequence as a template, we generated a Cx-EG2-(kss)4kk series of 218 
lipopeptoids, with x = 8, 11, 15, to examine how the length of the lipidic tail would influence the 219 
propensity of assembly. As shown in Figure 2A, we observed CACs of 200~220 µM (a.k.a. 220 
0.50~0.52 mg/mL, or 0.050~0.052 wt.%), with increasing lengths of the hydrophobic tail 221 
corresponding to lower CACs. These CACs are similar to the lowest values obtained in our first 222 
reports of lipopeptoid assembly (0.03~0.1 wt.%) [17] and are, in fact, relatively low for 223 
lipopeptides in general. DLS measurements of nanostructures with hydrodynamic radius (RH) in 224 
the range of ~40 nm (Figure 2C and D) further verified that our basic lipopeptoids design is viable.   225 
 226 
 227 
Figure 2. Plots of CACs (A and B) and hydrodynamic radii (C and D) of the kss lipopeptoids 228 
studied. The left column (A and C) shows the data for increasing tail length from C8, C11 to C15, 229 
for different lengths of the (kss)n motif, and the right column (B and D) shows the influence of the 230 
kk cationic headgroup and the EG2 linker, based on the (kss)4 motif and a C15 tail. 231 
Interestingly, effectively doubling the hydrophobic tail length (C8 vs. C15) only decreased CAC 232 
slightly by 10%. The corresponding increase in molecular weight of the lipopeptoids was from 233 
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2361 to 2459 g/mol, a 4% difference in mass, whereas the corresponding RH increases from 30 to 234 
45 nm for C8 to C15 was statistically marginal. However, there was a significant increase in RP-235 
HPLC retention off a hydrophobic column (increase from 48% to 65% ACN from C8 to C15) 236 
(Figure 3A). The above indicate that the lipid tail was not the main determinant of self-assembly 237 
in this system, with self-assembly being likely determined by a combination of other components, 238 
i.e. EG2, (kss)n motif, and the kk headgroup.  239 
 240 
 241 
Figure 3. Analytical RP-HPLC results of elution off a C18 column over a 5-95% ACN gradient for 242 
the kss family of lipopeptoids. (A) The length of the lipid tail Cx is varied: x = 8, 11, 15. (B) The 243 
length of the antimicrobial sequence (kss)n is changed: n = 2, 3, 4. (C) The arrangement of the EG2 244 
and kk segments is varied. The values labelling each data point is the elution ACN% of individual 245 
sequences.  246 
 247 
We next examined the assembly process with different lengths of the central antimicrobial (kss)n 248 
motif (n = 2, 3), using an intermediate C11 tail as an example (Figure 2A). In this case, the CAC 249 
became either moderately lower (198 µM/0.29 mg/mL for the shortest C11-EG2-(kss)2-kk) or 250 
higher (267 µM//0.52 mg/mL for C11-EG2-(kss)3-kk) than C11-EG2-(kss)4-kk. Although there was 251 
no apparent trend in CAC, the HPLC retention of the lipopeptoids (in %ACN) did increase with 252 
increasing number of kss motif repeats (Figure 3A). Therefore, longer (kss)n segments could 253 
contribute to an increased ability of the lipopeptoid to partition in a non-polar phase, as expected, 254 
but self-assembly was mostly driven by other effects. Since the tail length was also seen to weakly 255 
contribute, we next examined the arrangement of the lipopeptoids’ design components.  256 
We returned to the C15-EG2-(kss)4-kk base sequence to examine the influence of the kk and EG2 257 
insertions. The (kss)4 length was chosen because it has been reported to give the highest 258 
antimicrobial activity [29], and we chose the longest C15 tail because it is seen to confer the highest 259 
propensity to self-assemble, complementing our intention to minimize the CAC. Figure 2B shows 260 
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that removing the EG2 linker to obtain C15-(kss)4-kk resulted in assembly only at a much higher 261 
CAC of 304 µM (0.71 mg/mL). On the other hand, removing the charged kk head group to form 262 
C15-EG2-(kss)4 dramatically decreased CAC to a very low 38 µM (0.075 mg/mL, or 0.0075 wt.%; 263 
Figure S6).  264 
The decrease in CAC with removal of kk (i.e. C15-EG2-(kss)4) was accompanied by a greatly 265 
increased HPLC elution to 82% ACN from 65% ACN (C15-EG2-(kss)4-kk; Figure 2B) while 266 
removing EG2 but retaining kk caused essentially no change in the retention (66% ACN). 267 
Ordinarily, peptoids/peptides eluting at these relatively high ACN contents would precipitate in 268 
aqueous buffers. This was not observed, which is consistent with solubility of the material enabled 269 
by micellization.  270 
Formation of nano-assemblies from C15-EG2-(kss)4 was further confirmed by DLS observations, 271 
which here gave RH of ca. 50 nm (Figure 2D). To corroborate DLS results complementary 272 
structural characterizations by SAXS and cryo-TEM were also performed. SAXS indicates the 273 
presence of nano-assemblies 24±5 nm in radius (Figure S7A and Table S1). TEM shows that some 274 
of these assemblies actually comprise of non-compact aggregates as small as ca. 5 nm diameter 275 
(Figure S7B). Irregularity in shape would have contributed to relatively larger hydrodynamic sizes 276 
measured by DLS. On the other hand, the smallest features seen by TEM could have been missed 277 
by DLS and SAXS since scattering signals scale significantly with particle size. 278 
In our initial report of lipopeptoid self-assembly [17], we speculated that bending along the 279 
lipopeptoid backbone could enable insertion of lipid tails towards a hydrophobic central core while 280 
allowing the amphiphilic peptoid sequence to lie parallel to the micelles’ outer surface, with 281 
ionizable groups facing the external aqueous environment. The increase in CAC with removal of 282 
EG2 is consistent with this view, since assembly would be less favorable without the EG2 linker 283 
enhancing flexibility between the aliphatic tail and the peptoid sequence. The much lower CAC 284 
after removing the charged kk “headgroup” is also in agreement with the aforementioned 285 
hypothesis, since removing this headgroup would reduce charge repulsion between peptoids and 286 
enhance uniformity of the micelle’s outer shell.  287 
 288 
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 289 
Figure 4. CAC (A) and analytical RP-HPLC (B) results of the 4/5k family of lipopeptoids with 290 
tail lengths of C8 and C15. HPLC elution was carried out using a C18 column and a 5-95% ACN 291 
gradient.   292 
 293 
3.3. Self-Assembly of 4/5k Lipopeptoids  294 
Lipopeptoids of the 4/5k family generally exhibited a lower assembly propensity than the kss 295 
lipopeptoids, and the aliphatic tail length had a much greater influence on their self-assembly. 296 
Figure 4A shows that 4/5k lipopeptoids with C15 tails all exhibited a CAC around 300~400 µM 297 
(0.50~0.65 mg/mL), while those with C8 tails exhibited CAC at least 3-times higher (i.e. low 298 
assembly propensity), from 1600 to 2500 µM (2.4~3.7 mg/mL). Accordingly, analytical HPLC 299 
showed that the much lower CACs, associated with the longer C15 tails, were correlated with 300 
substantially higher retention and hydrophobicity (from 67 to 78 %ACN; Figure 4B) than that 301 
exhibited by the C8 series (from 48 to 55 %ACN). However, differences between the 4/5k peptoid 302 
sequences appear to play a less important role in the CAC (i.e., assembly process) at each 303 
individual tail length. Although CAC at the C15 tail length did indeed decrease from  410 ± 32 to 304 
320 ± 24 µM according to increasing HPLC retention from 67 to 78 ACN% (counting from kykbk, 305 
5k, to 4k), the trend at the C8 tail length is less clear—the most hydrophobic 4k actually resulted 306 
in the highest CAC (2500 ± 350 µM) and the kykbk and 5k sequences generated statistically 307 
similar CAC despite their significantly different retentions (i.e. 1900 ± 200/1600 ± 390 µM and 308 
48/52 %ACN for kykbk/5k).   309 
In comparison, the tail length and the kss repeat length for the kss family of lipopeptoids had a 310 
limited influence on the CAC (Figure 2A and B). A significant difference between the two families 311 
is the distribution of hydrophobic and cationic residues along the antimicrobial peptoid sequences. 312 
The kss sequences express a regular repeating kss trimer motif that induces a helical conformation 313 
placing all the cationic sidechains on one face of this helix. In contrast, the 4/5k sequences have a 314 
pronounced head-to-tail switch in hydrophobicity, with many water soluble cationic Nlys residues 315 
placed towards the C-terminus (thus no additional kk headgroup is added to the 4/5k lipopeptoids) 316 
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and multiple hydrophobic residues placed towards the C-terminus (Figure 1D). As such, the 4/5k 317 
lipopeptoids resemble conventional surfactants, with a defined soluble head group and a 318 
hydrophobic tail. Indeed, it seems plausible that the peptoid conformations within the self-319 
assemblies would be different between the two families, with the conventional surfactant 320 
configuration of the 4/5k lipopeptoids allowing for more control of the CAC via the tail length 321 
changes. These differences between the overall distribution in hydrophobic sequence regions and 322 
our hypothesis of the subsequent effects on assembly are summarized in Figure 5. Overall, a very 323 
large contribution of the hydrophobic tail is needed to sway the assembly behavior, whereas 324 
differences in conformations and hydrophobicity distributions of the two series (i.e. helical kss, 325 
head-tail amphiphilic 4/5k series and kk head group, flexible EG2 linker) appear to strongly 326 
contribute to the assembly process.   327 
 328 
Figure 5. Schematics illustrating hypothetical differences and similarities in lipopeptoid 329 
arrangements in nano-assemblies due to different conformations and hydrophobicity distributions. 330 
Water-soluble cationic groups on one face of helical kssn may constrain changes in hydrophobic 331 
interactions and size of nano-assemblies, even if different lengths of lipidic tails are used (A and 332 
B). The head-tail surfactant-like 4/5k may lead to more conventional assemblies controlled by 333 
length of lipidic tails (C and D). The low assembly propensity (high CAC) of C8-EG2-4/5k is 334 
indicated by their irregular, looser packing. The overlapping micelles illustrate the possibility of 335 
aggregates in generating some of the large sizes measured by DLS. Different micelle morphologies 336 
may also be possible but are not shown. 337 
 338 
3.4. Antibacterial MIC Measurements  339 
We measured the minimum inhibitory concentration (MICs) of our lipopeptoids for the Gram 340 
positive Staphylococcus aureus and the Gram negative Escherichia coli and Pseudomonas 341 
aeruginosa. The results for Cx-EG2-(kss)n-kk series are shown in Figure 6. The bacteria here are 342 
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presumed to be interacting with individually dissolved lipopeptoids as the MICs measured are all 343 
below the CACs obtained (Figure 2). 344 
Three main effects were observed. First, the MICs for the (kss)3 and (kss)4 lipopeptoids at the C8 345 
and C11 tail lengths were largely unchanged compared to the native unmodified AMPM, providing 346 
evidence that these AMPMs are amenable to chain end modifications. This opens the door to 347 
adapting these sequences for different applications, such as the present case of micellar self-348 
assembly. Second, cases were observed where the lipopeptoids can become more active (decreased 349 
MIC). Specifically, C11-EG2-(kss)2-kk exhibited lower MICs than their respective native 350 
sequences against all strains tested (i.e. 40~50 µM vs. 10~20 µM). The C8-EG2-(kss)4-kk also 351 
exhibited a slightly lower MIC against P. aeruginosa (16 µM vs. 5 µM). Third, the MICs at the 352 
C15 tail length increased significantly for all strains tested.  353 
 354 
 355 
Figure 6. MICs against E. coli (A), P. aeruginosa. (B), and S. aureus (C) measured for C8-EG2-356 
(kss)n-kk lipopeptoids with increasing tail length C8, C11 and C15, and different lengths of the (kss)n 357 
motif. Values measured for “unfunctionalized” (kss)n peptoids are also shown. The legend in panel 358 
A applies to all data. The error bars denote ±1 SD (standard deviation). Bounded boxes with an up 359 
arrow denote that no significant inhibition was observed up to the maximum tested 100 µM—the 360 
actual MICs could be significantly higher. Dashed lines highlight the corresponding data points in 361 
a series. 362 
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The increase in effectiveness for the (kss)2 is interesting, as this short length is the least effective 364 
version of the kss AMPM reported. Addition of a lipophilic tail generates a more surfactant-like 365 
molecule and presumably assisted in membrane interactions, an effect that had been reported [33]. 366 
However, for an AMPM that already has a length suitable for membrane interactions (i.e. the 12-367 
mer (kss)4), addition of a lipid tail (e.g. C15-EG2-(kss)4-kk) did, in fact, interfere with its activity.   368 
Figure 7 shows the effect on the MIC after removing EG2 or kk units while maintaining the C15 369 
tail length. It is seen that C15-(kss)4-kk exhibited a dramatically increased MICs (lowered activity) 370 
above 100 µM for all bacteria tested, higher than for the range observed for C15-EG2-(kss)4-kk 371 
(Figure 6), and much higher than the 5~16 µM MICs of the native (kss)4. As such, the EG2 linker 372 
appears to be necessary to separate the lipid tail from the (kss)4 sequence for bacterial interactions. 373 
However, removing kk For C15- EG2-(kss)4 also caused increases in MIC, to >100 µM against both 374 
E. coli and P. aeruginosa, and ~50 µM against S. aureus. For this sequence, the CAC at 34 µM 375 
(Figure 2B) was lower than the MIC. Thus, these increased MICs could be an apparent effect due 376 
to packing of the AMPMs in nano-assemblies. Future studies will be required to investigate release 377 
mechanisms and the corresponding activities for those assemblies at concentrations above the 378 
CAC and below the apparent MIC. 379 
 380 
 381 
Figure 7. MICs against E. coli, P. aeruginosa, and S. aureus for (kss)4 lipopeptoids with C15 tails 382 
but without either the kk or EG2 components. The error bars denote ±1 SD. Bounded boxes with 383 
an up arrow denote that no significant inhibition was observed up to the maximum tested 100 384 
µM—the actual MICs could be significantly higher. Dashed lines highlight the corresponding data 385 
points in a series. 386 
 387 
The MICs for the 4/5k family of lipopeptoids are shown in Figure 8. Given the results for the kss 388 
lipopeptoids, the EG2 linker was always retained. Moreover, given the very high CACs of the 4/5k 389 
lipopeptoids, it is assumed that the interactions observed can all be assigned to individual chains, 390 
especially for the C8 series. Overall, no significant effect was observed after modifying the N-391 
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terminus with the shorter C8 tail, except for the 5k sequence against the Gram-negative E. coli and 392 
P. aeruginosa, for which the MIC increased. Secondly, lengthening the tail to C15 significantly 393 
increased the MIC in general, in many cases to above 100 µM. This paralleled the MIC increases 394 
for C15-EG2-(kss)4-kk (Figure 6). At the same time, given the ability of the C15 tail to decrease the 395 
CAC for 4/5k lipopeptoids, compared to the C8 tails, it would appear that the assembly-promoting 396 
properties of the C15-EG2 combination (Figure 2B and Figure 4) also interfered, in general, with 397 
antimicrobial activity.  398 
 399 
  400 
Figure 8. MICs against E. coli (A), P. aeruginosa. (B), and S. aureus (C) for 4/5k lipopeptoids 401 
with C8 and C15 tails compared with the native AMPM sequence. The error bars denote ±1 SD. 402 
Bounded boxes with an up arrow denote that no significant inhibition was observed up to the 403 
maximum tested 100 µM—the actual MICs could be significantly higher. Dashed lines highlight 404 
the corresponding data points in a series. 405 
 406 
4. Discussion and Conclusion 407 
This work investigates the interplay between self-assembly and antimicrobial activity for a series 408 
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peptoids. The effects of coupling a diethylene glycol “EG2” linker and lipid tails of varying lengths 410 
to the N-terminus, and a “kk” di-Nlys cationic headgroup to the C-terminus, were evaluated.  411 
Lipopeptoids based on the “kss” family of helical AMPMs exhibited low CACs, generally around 412 
200~400 µM (0.05~0.1 wt.%). These values are low for relatively small self-assembling species 413 
such as our lipopeptoids and indicate a strong propensity for self-assembly. Surprisingly, the length 414 
of the hydrophobic tail was found to only have a slight effect on assembly, and the solubilizing kk 415 
headgroup actually increased the CAC. However, an EG2 greatly enhanced self-assembly, and a 416 
very low CAC of 38 µM (0.0075 wt.%) was found for a C15-EG2-(kss)4 design. For 4/5k 417 
lipopeptoids, the kk headgroup is an intrinsic part of the antimicrobial sequence and the tail length 418 
became a controlling influence on assembly. Although we carried out our CAC characterization 419 
in water, fundamental thermodynamic forces generally drive micellar systems to lower CACs (i.e. 420 
higher assembly propensity) in higher buffer/salt conditions. However, instabilities resulting from 421 
uncontrolled aggregation may result in practice [34, 35]. 422 
Overall, the high assembly propensity of C15-EG2-(kss)4 could be associated with the 423 
unconventional linking (via use of a flexible EG2 unit) of a hydrophobic tail to a helical kss peptoid 424 
presenting cationic sidechains segregated to one side of the helix. We speculate that this design 425 
could enable an arrangement of kss peptoids parallel to the surfaces of micelles overshadowing 426 
the contribution of different lipid tail lengths to self-assembly. In contrast, markedly different 427 
assembly properties were observed with the head-to-tail amphiphilicity of 4/5k peptoids, which 428 
follow the expected lipid tail length dependencies.  429 
The antimicrobial activities of the lipopeptoids, on the other hand, depended significantly on the 430 
hydrophobic tail length for both the kss and 4/5k designs. Many of our lipopeptoids with a C8 or 431 
C11 tail either preserved, or even decreased, the MICs compared to the native sequences. However, 432 
MICs increased significantly with a C15 tail. In evaluating activity, lowered MICs compared to the 433 
unmodified AMPM would be of interest if the lipopeptoid were interacting as individual 434 
molecules, as would be the case at concentrations below the CAC. Given the high potency of the 435 
AMPMs studied (100 ~ 101 µM), almost all the lipopeptoids we generated exhibited CACs (≳102 436 
µM) above their MICs (100 ~ 102 µM). Thus, most of our lipopeptoids would be interacting as 437 
solubilized species in the unassembled state.   438 
We were also interested in increases in the MIC in combination with a low CAC. We hypothesized 439 
that packing of AMPMs into molecularly large nano-assemblies would interfere with regular 440 
membrane interactions necessary for activity, and hence induce an apparent increase in MIC. This 441 
would pave way to AMPMs (and analogous AMP designs) that may remain “inert” in the 442 
environment, even if unintentionally released, and hence prevent microbes from gaining active 443 
exposure and developing resistance. The sequence C15-EG2-(kss)4 satisfied these criteria, 444 
exhibiting a CAC of 38 µM (0.0075 wt.%) combined with an MIC of 40 µM against the Gram-445 
positive S. aureus and above 100 µM against the Gram-negative E. coli and P. aeruginosa strains 446 
tested. Further physical characterization by SAXS, TEM and DLS showed corresponding nano-447 
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assemblies ~40 nm in radius. Based on the trends observed in the current study, future work will 448 
be aimed at discovering more species with properties similar to or better than C15-EG2-(kss)4, and 449 
at investigating release mechanisms and the potency of the released sequences. 450 
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